Please login to the form below

Not currently logged in
Email:
Password:

anacetrapib

This page shows the latest anacetrapib news and features for those working in and with pharma, biotech and healthcare.

CETP inhibitor class finally dies as Merck abandons anacetrapib

CETP inhibitor class finally dies as Merck abandons anacetrapib

CETP inhibitor class finally dies as Merck abandons anacetrapib. Cholesterol drug fails to “support regulatory filings”. ... and there was also evidence that anacetrapib accumulates in fat tissue with prolonged dosing, which could raise safety issues.

Latest news

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    Whilst Roche and Pfizer failed to overcome efficacy and safety concerns regarding their candidates, Eli Lilly's (evacetrapib) and Merck's (anacetrapib), products are looking to raise HDL levels and these

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics